Sign in

CIK 0001649989

  • Non-accelerated filer
  • Smaller reporting company

Outlook Therapeutics, Inc.

Sign in to watch
Ticker
OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Sep 30
Incorporated
DE
Entity type
Operating
EIN
383982704
Phone
+1 609-619-3990
Business address
111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
Former names
Oncobiologics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 71 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2019-10-03 Haddadin Yezan Munther Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2019-10-03 Haddadin Yezan Munther Director Grant or award · Stock Option (Right to Buy) +80,176 $0.99 $79K 80,176
2019-10-03 Thomas Joe Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2019-10-03 Thomas Joe Director Grant or award · Stock Option (Right to Buy) +48,207 $0.99 $47K 48,207
2019-10-03 Sukhtian Faisal Ghiath Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2019-10-03 Sukhtian Faisal Ghiath Director Grant or award · Stock Option (Right to Buy) +86,772 $0.99 $85K 86,772
2019-10-03 THURMAN RANDY H Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2019-10-03 THURMAN RANDY H Director Grant or award · Stock Option (Right to Buy) +207,036 $0.99 $204K 207,036
2019-10-03 HILZINGER KURT J Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2019-10-03 HILZINGER KURT J Director Grant or award · Stock Option (Right to Buy) +60,893 $0.99 $60K 60,893
2019-09-30 BioLexis Pte Ltd. Director Other acquisition · Series A-1 Convertible Preferred Stock +1,620 66,451
2019-09-18 KENYON LAWRENCE A CEO, Pres, CFO, Treas & Secy Sale −1,350 $1.70 $2K 8,926
2019-09-18 KENYON LAWRENCE A CEO, Pres, CFO, Treas & Secy Sale −1,350 $1.70 $2K 80,863
2019-09-12 KENYON LAWRENCE A CEO, Pres, CFO, Treas & Secy Grant or award · Stock Option (Right to Buy) +450,000 450,000
2019-06-30 BioLexis Pte Ltd. Director Other acquisition · Series A-1 Convertible Preferred Stock +1,581 64,831
2019-06-17 BioLexis Pte Ltd. Director Option exercise +2,181,818 14,039,494
2019-06-17 BioLexis Pte Ltd. Director Option exercise · Warrant (Right to Buy) −3,636,364 0
2019-04-12 BioLexis Pte Ltd. Director Grant or award +3,636,364 $2.75 $10.0M 11,857,676
2019-04-12 BioLexis Pte Ltd. Director Grant or award · Warrant (Right to Buy) +3,636,364 3,636,364
2019-04-12 BioLexis Pte Ltd. Director Grant or award · Warrant (Right to Buy) +3,636,364 3,636,364

Page 13 of 14 · 276 trades